58131-57-0

Basic information

• Product Name: NSC 207895
• Synonyms: 4-(4-Methyl-1-piperazinyl)-7-nitrobenzofurazan 3-oxide;4-(4-Methyl-1-piperazinyl)-7-nitrobenzofurazane 3-oxide;7-(4-Methyl-1-piperazinyl)-4-nitrobenzofurazane 1-oxide;XI-006 (NSC207895)=1119;NSC-207895;NSC-207895 (XI-006);NSC 179940;4-(4-Methyl-1-piperazinyl)-7-nitro-2,1,3-benzoxadiazole 3-oxide
• CAS NO: 58131-57-0
• Molecular Formula: C11H13N5O4
• Molecular Weight: 279.25
• EINECS: 200-258-5
• Product Categories: Inhibitor;Inhibitors
• Mol File: 58131-57-0.mol

Chemical Properties

• Boiling Point: 487.6°C at 760 mmHg
• Flash Point: 248.7°C
• Appearance: /
• Density: 1.64
• Vapor Pressure: 1.17E-09mmHg at 25°C
• Refractive Index: 1.737
• Solubility: Limited solubility
• PKA: 6.23±0.42(Predicted)
• CAS DataBase Reference: NSC 207895(CAS DataBase Reference)
• NIST Chemistry Reference: NSC 207895(58131-57-0)
• EPA Substance Registry System: NSC 207895(58131-57-0)

Safety Data

• Hazardous Substances Data: 58131-57-0(Hazardous Substances Data)

Usage

Uses

Used in Anticancer Applications:
NSC 207895 is used as an anticancer agent for its ability to activate p53 and inhibit the p53-binding protein MDMX. This leads to a decrease in MDMX expression and an increase in the expression of p53 target genes, such as CDKN1 (p21), PUMA, Bax, and PIG3. NSC 207895 induces apoptosis and decreases cell viability in a p53-dependent manner in various cancer cell lines, including MCF-7 cells overexpressing MDMX and Ewing sarcoma cell lines with wild-type, mutated, and truncated p53.
Used in Antibiotic Revival:
NSC 207895 is used as a pharmacological agent for reviving the effectiveness of antibiotics by acting as an efflux pump inhibitor. It targets the AcrA membrane fusion protein of the AcrAB-TolC multidrug efflux pump, which is involved in the resistance of bacteria to antibiotics. By inhibiting this protein, NSC 207895 can potentially restore the sensitivity of bacteria to antibiotics, overcoming the challenge of antibiotic resistance.
Used in Drug Delivery Systems:
Although not explicitly mentioned in the provided materials, NSC 207895 could potentially be used in drug delivery systems to improve its bioavailability and therapeutic outcomes. This could involve the development of novel drug delivery systems, such as organic and metallic nanoparticles, to enhance the delivery and efficacy of NSC 207895 in cancer treatment and antibiotic revival applications.

references

[1] hawes jj, nerva jd, reilly km. novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds. j biomol screen. 2008 sep;13(8):795-803. [2] wang h, ma x, ren s, buolamwini jk, yan c. a small-molecule inhibitor of mdmx activates p53 and induces apoptosis. mol cancer ther. 2011 jan;10(1):69-79. [3] kapitzky l, beltrao p, berens tj, gassner n, zhou c, wüster a, wu j, babu mm, elledge sj, toczyski d, lokey rs, krogan nj. cross-species chemogenomic profiling reveals evolutionarily conserved drug mode of action. mol syst biol. 2010 dec 21;6:451.

InChI:InChI=1/C11H13N5O4/c1-13-4-6-14(7-5-13)9-3-2-8(15(17)18)10-11(9)16(19)20-12-10/h2-3H,4-7H2,1H3